Open Access

Integrated analysis of long non‑coding RNA megacluster, microRNA‑132 and microRNA‑133a and their implications for cardiovascular risk and kidney failure progression in diabetic patients 

  • Authors:
    • Gehad Abdelgayed
    • Ahmed Hosni
    • Adel Abdel‑Moneim
    • Abdul Malik
    • Mohamed Y. Zaky
    • Nabil A. Hasona
  • View Affiliations

  • Published online on: December 18, 2024     https://doi.org/10.3892/etm.2024.12785
  • Article Number: 35
  • Copyright: © Abdelgayed et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Inefficient control of elevated blood sugar levels can lead to certain health complications such as diabetic nephropathy (DN) and cardiovascular disease (CVD). The identification of effective biomarkers for monitoring diabetes was performed in the present study. The present study aimed to investigate the implications of long non‑coding RNA megacluster (lnc‑MGC), microRNA (miR)‑132 and miR‑133a, and their correlation with lactate dehydrogenase (LDH) activity and glycated hemoglobin (HbA1C) levels to identify biomarkers for the early diagnosis of diabetes mellitus, induced DN and CVD. The present study included a total of 200 patients with type 2 diabetes, as well as 40 healthy subjects as controls. The diabetic patients were classified into six groups based on their estimated HbA1c level, glomerular filtration rate and LDH activity, while the healthy controls constituted the seventh group. Diabetic patients exhibited significant increases in parameters related to diabetes as fasting blood sugar, HbA1c levels, cardiac injury and kidney failure. Furthermore, the expression levels of TNF‑α were significantly increased in the diabetic groups compared with healthy controls. Diabetic patients with cardiovascular dysfunction showed significantly increased expression levels of miR‑132, miR‑133a and lnc‑MGC, compared with the healthy group. The expression of circulating miR‑132 in blood was low in the groups of diabetic patients compared with the healthy controls, and demonstrated a negative correlation with LDH and HbA1C levels. Expression levels of miR‑132, miR‑133a and lnc‑MGC, along with their correlations with LDH and HbA1C levels, could be used to distinguish diabetic patients with reduced CVD from those at early stage diabetes, which indicated their potential as biomarkers for CV complications associated with diabetes mellitus in the future.

Related Articles

Journal Cover

February-2025
Volume 29 Issue 2

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Abdelgayed G, Hosni A, Abdel‑Moneim A, Malik A, Zaky MY and Hasona NA: Integrated analysis of long non‑coding RNA megacluster, microRNA‑132 and microRNA‑133a and their implications for cardiovascular risk and kidney failure progression in diabetic patients . Exp Ther Med 29: 35, 2025.
APA
Abdelgayed, G., Hosni, A., Abdel‑Moneim, A., Malik, A., Zaky, M.Y., & Hasona, N.A. (2025). Integrated analysis of long non‑coding RNA megacluster, microRNA‑132 and microRNA‑133a and their implications for cardiovascular risk and kidney failure progression in diabetic patients . Experimental and Therapeutic Medicine, 29, 35. https://doi.org/10.3892/etm.2024.12785
MLA
Abdelgayed, G., Hosni, A., Abdel‑Moneim, A., Malik, A., Zaky, M. Y., Hasona, N. A."Integrated analysis of long non‑coding RNA megacluster, microRNA‑132 and microRNA‑133a and their implications for cardiovascular risk and kidney failure progression in diabetic patients ". Experimental and Therapeutic Medicine 29.2 (2025): 35.
Chicago
Abdelgayed, G., Hosni, A., Abdel‑Moneim, A., Malik, A., Zaky, M. Y., Hasona, N. A."Integrated analysis of long non‑coding RNA megacluster, microRNA‑132 and microRNA‑133a and their implications for cardiovascular risk and kidney failure progression in diabetic patients ". Experimental and Therapeutic Medicine 29, no. 2 (2025): 35. https://doi.org/10.3892/etm.2024.12785